ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1678 • ACR Convergence 2021

    Favorable Balance of Benefit and Harm of Long-Term, Low Dose Prednisolone Added to Standard Treatment in Rheumatoid Arthritis Patients Aged 65+: The Pragmatic, Multicenter, Placebo-Controlled GLORIA Trial

    Maarten Boers1, Linda Hartman1, Daniela Opris-Belinski2, Reinhard Bos3, Marc Kok4, Jose Pereira da Silva5, Ed Griep6, Ruth Klaasen7, Cornelia F. Allaart8, Paul Baudoin9, Hennie Raterman10, Zoltan Szekanecz11, Frank Buttgereit12, Pavol Masaryk13, L. Thomas Klausch1, Sabrina Paolino14, Annemarie Schilder3, Willem Lems15 and Maurizio Cutolo14, 1Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 2Carol Davila University, Bucharest, Romania, 3Medical Center Leeuwarden, Leeuwarden, Netherlands, 4Maasstad Hospital, Rotterdam, Netherlands, 5University of Coimbra | UC · Clínica Universitária de Reumatologia. Faculty of Medicine, Columbia, Portugal, 6Antonius Hospital, Sneek, Netherlands, 7Meander Medical Center, Amersfoort, Netherlands, 8Leiden University Medical Center, Leiden, Netherlands, 9Reumazorg Flevoland, Emmeloord, Netherlands, 10Northwest Clinics, Alkmaar, Netherlands, 11Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary, 12Charité – Universitätsmedizin Berlin, Berlin, Germany, 13National Institute for the Rheumatic Diseases, Bratislava, Slovakia, 14Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy, 15VUmc, Amsterdam, Netherlands

    Background/Purpose: Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis (RA) but the balance of benefit and harm is still unclear. We studied the…
  • Abstract Number: 1671 • ACR Convergence 2021

    COVID-19 in Patients with Rheumatoid Arthritis Compared to Patients with Osteoarthritis During the Pandemic in New York City

    Jonah Levine1, Vivian Bykerk2, Lindsay Lally1, Lisa Mandl1 and Medha Barbhaiya1, 1Hospital for Special Surgery, New York, NY, 2Division of Rheumatology, Hospital for Special Surgery, New York City, NY

    Background/Purpose: COVID-19 in patients with rheumatoid arthritis (RA) is poorly understood. A recent study of mostly men with RA demonstrated increased COVID-19 risk in RA…
  • Abstract Number: 1691 • ACR Convergence 2021

    Long-Term Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis

    Gerd Burmester1, Stanley Cohen2, Kevin Winthrop3, Peter Nash4, Andrea Rubbert-Roth5, Atul Deodhar3, Ori Elkayam6, Eduardo Mysler7, Yoshiya Tanaka8, Jianzhong Liu9, Ana Paula Lacerda9, Bosny Pierre-Louis9, Tim Shaw10 and Philip Mease11, 1Charité University Medicine Berlin, Berlin, Germany, 2Metroplex Clinical Research Center, Dallas, TX, 3Oregon Health & Science University, Portland, OR, 4Griffith University, Brisbane, Australia, 5Kantonspital St Gallen, St.Gallen, Switzerland, 6Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 7Organización Medica de Investigación, Rheumatology, Buenos Aires, Argentina, 8University of Occupational and Environmental Health, Kitakyushu, Japan, 9AbbVie Inc., North Chicago, IL, 10AbbVie Inc., North Chicago, 11Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA

    Background/Purpose: The efficacy and safety of the oral Janus kinase inhibitor, upadacitinib (UPA), has been evaluated for several rheumatic diseases. The objective of this analysis…
  • Abstract Number: 1690 • ACR Convergence 2021

    Safety and Efficacy of Long-term Sarilumab Treatment in Patients with Active Rheumatoid Arthritis: EXTEND and MONARCH Open Label Extension Studies

    Gerd Burmester1, Vibeke Strand2, Alan Kivitz3, Chih-Chi Hu4, Sheldon Wang4, Hubert van Hoogstraten5, Ray Tao6 and Roy Fleischmann7, 1Charité University Medicine Berlin, Berlin, Germany, 2Stanford University School of Medicine, Portola Valley, CA, 3Altoona Center for Clinical Research, Duncansville, PA, 4Sanofi Genzyme, Bridgewater, NJ, 5Sanofi, Bridgewater, NJ, 6Sanofi China R&D, Shanghai, China (People's Republic), 7Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: In patients who experience intolerance or fail to respond to methotrexate, IL-6 receptor inhibitors (e.g. sarilumab) are one of the recommended options. The aim…
  • Abstract Number: 1681 • ACR Convergence 2021

    ATI-450, an Investigational MK2 Inhibitor, Is Well Tolerated and Demonstrated Clinical Activity in Patients with Mod/severe RA: A 12-week Phase 2a, Randomized, Investigator/patient-blind Study Investigating the Safety, Tolerability, PK and PD of ATI-450 + MTX vs PBO + MTX in MTX IR Patients

    Alan Kivitz1, Joe Monahan2, David Burt3, Marco Cardillo3, Heidi Hope2 and David Gordon3, 1Altoona Center for Clinical Research, Duncansville, PA, 2Aclaris Therapeutics, St Louis, MO, 3Aclaris Therapeutics, Wayne, PA

    Background/Purpose: p38 inhibition has been a focus of research in RA but efficacy in clinical studies was underwhelming, possibly because a large number of pro…
  • Abstract Number: 1685 • ACR Convergence 2021

    Efficacy and Safety of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – Placebo and Active Controlled Study

    Eugen Feist1, Saeed Fatenejad2, Sergey Grishin3, Elena Korneva3, Evgeniy Nasonov4, Anna Rowińska-Osuch5, Mikhail Samsonov6 and Roy Fleischmann7, 1Helios Department of Rheumatology, Vogelsang-Gommern, Germany, 2SFC Medica, LLC, Charlotte, NC, 3R-Pharm, Moscow, Russia, 4V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia, 5MCM Polimedica, Warsaw, Poland, 6RPharm, Moscow, Russia, 7Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Olokizumab (OKZ) is a humanized monoclonal antibody targeting IL-6 [1]. Here we present the results of a global phase III, head-to-head, randomized placebo (PBO)…
  • Abstract Number: 1698 • ACR Convergence 2021

    Integrated Safety Analysis Update for Filgotinib in Patients with Moderately to Severely Active Rheumatoid Arthritis Receiving Treatment over a Median of 2.2 Years

    Kevin Winthrop1, Yoshiya Tanaka2, Tsutomu Takeuchi3, Alan Kivitz4, Mark Genovese5, Alena Pechonkina6, Franziska Matzkies6, Beatrix Bartok7, Kun Chen6, Deyuan Jiang6, Iyabode Tiamiyu6, Robin Besuyen8, Sander Strengholt9, Gerd Burmester10 and Jacques-Eric Gottenberg11, 1Oregon Health & Science University, Portland, OR, 2University of Occupational and Environmental Health, Kitakyushu, Japan, 3Div. Rheumatology, Keio University, Tokyo, Japan, 4Altoona Center for Clinical Research, Duncansville, PA, 5Gilead Sciences, Inc., Sunnyvale, CA, 6Gilead Sciences, Inc., Foster City, CA, 7Gilead Sciences, Inc., La Jolla, CA, 8Galapagos BV, Leiden, Netherlands, 9Galapagos, BV, New York, NY, 10Charité University Medicine Berlin, Berlin, Germany, 11National Reference Center for Rare East South-West Autoimmune Systemic Diseases RESO, Strasbourg University Hospitals, Strasbourg, France

    Background/Purpose: The preferential Janus kinase (JAK)-1 inhibitor filgotinib (FIL) significantly improved signs and symptoms of RA in Phase 2 and 3 trials,1–5 and FIL is…
  • Abstract Number: 1693 • ACR Convergence 2021

    Lower Adverse Event and Infection Rates During Tocilizumab Therapy Without Concomitant GC: An Analysis of the ICHIBAN Study

    Christof Specker1, Martin Aringer2, Gerd Burmester3, Marvin A. Peters4, Michael W. Hofmann5, Herbert Kellner6, Frank Moosig7, Hans-Peter Tony8 and Gerhard Fliedner9, 1Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany, 2Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, 3Charité University Medicine Berlin, Berlin, Germany, 4Roche Pharma AG, Grenzach-Wyhlen, Germany, 5Chugai Pharma Germany GmbH, Frankfurt am Main, Germany, 6Hospital Neuwittelsbach, Center for Rheumatology and Gastroenterology, Munich, Germany, Munich, Germany, 7Rheumatology Center Schleswig-Holstein Middle, Neumünster, Germany, 8Universitätsklinikum Würzburg, Wuerzburg, Germany, 9Rheumatology Practice, Osnabrueck, Germany

    Background/Purpose: To limit the risk of serious infections, guidelines recommend short term (< 3 months) or low-dose (≤10 mg/day) adjunct glucocorticoids (GCs) to control rheumatoid…
  • Abstract Number: 1689 • ACR Convergence 2021

    Safety, Tolerability, Pharmacokinetics, Receptor Occupancy, and Suppression of T-cell-Dependent Antibody Response in a Phase 1 Study with KPL-404, an anti-CD40 Monoclonal Antibody

    Manoj Samant1, Alistair Wheeler2, Guang-Liang Jiang1, Moses Njenga1, Madeline Spiers1, Arian Pano1 and John F Paolini1, 1Kiniksa Pharmaceuticals Corp., Lexington, MA, 2Kiniksa Pharmaceuticals, Ltd., Hamilton, Bermuda

    Background/Purpose: T-cell priming and T-cell-dependent B-cell responses require an intact cluster of differentiation (CD)40/CD40L pathway. CD40 is expressed on the surface of B-cells, dendritic cells,…
  • Abstract Number: 1653 • ACR Convergence 2021

    Positron Emission Tomography-Detected Uptake of 18F-Fluorodeoxyglucose in Visceral and Subcutaneous Adipose Tissue Is Associated with Articular Disease Activity and Arterial Inflammation in Rheumatoid Arthritis

    Jon Giles1, Joan Bathon2, Hadil Zureigat3 and Ahmed Tawakol4, 1Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, 2Columbia University, New York, NY, 3Harvard University, Boston, MA, 4Harvard University/Massachusetts General Hospital, Boston, MA

    Background/Purpose: Subcutaneous adipose tissue (SAT) from people with RA contains more macrophages and expresses higher levels of cytokines, chemokines, and other inflammatory mediators compared with…
  • Abstract Number: 1662 • ACR Convergence 2021

    Unrecognised, Subclinical, Structural or Functional Lung Changes in Rheumatoid Arthritis Is Associated with a Higher Risk of Developing Serious Respiratory Tract Infection

    Benjamin Worcester1, Dorothy Wang2, Susan Morton3 and Michelle Leech4, 1Monash Health, Melbourne, Australia, 2Melbourne Health, Clayton, Australia, 3Monash Health, Clayton, Australia, 4Monash Medical Centre, Australia, Australia

    Background/Purpose: The incidence of lung disease within the rheumatoid arthritis is well described and likely underestimated. Additionally, RA patients are at higher risk for developing…
  • Abstract Number: 1684 • ACR Convergence 2021

    Incidence of Infections in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors

    Andra R Bălănescu1, Gustavo Citera2, Virginia Pascual-Ramos3, Carol A Connell4, David Gold5, All-shine Chen4, Harry Shi6, Andrea B Shapiro7, Janet Pope8 and Hendrik Schulze-Koops9, 1“Carol Davila” University of Medicine and Pharmacy, Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, 2Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 3Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 4Pfizer Inc, Groton, CT, 5Pfizer Inc, Montréal, QC, Canada, 6Pfizer Inc, Collegeville, PA, 7Pfizer Inc, Peapack, NJ, 8University of Western Ontario, London, ON, Canada, 9Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany

    Background/Purpose: Previous clinical trial and real-world data suggest that risk of serious infection events (SIEs) and opportunistic infections (OIs) is similar with tofacitinib 5 mg…
  • Abstract Number: 1696 • ACR Convergence 2021

    Clinical Outcomes up to Week 48 of Ongoing Filgotinib RA Long-term Extension Trial of Biologic DMARD Inadequate Responders Initially on Filgotinib or Placebo in a Phase 3 Trial

    Maya Buch1, Tsutomu Takeuchi2, Vijay Rajendran3, Jacques-Eric Gottenberg4, Alena Pechonkina5, YingMeei Tan6, Qi Gong5, Katrien Van Beneden7 and Roberto Caporali8, 1University of Leeds, Leeds, United Kingdom, 2Div. Rheumatology, Keio University, Tokyo, Japan, 3Galapagos NV, Mechelen, Belgium, 4National Reference Center for Rare East South-West Autoimmune Systemic Diseases RESO, Strasbourg University Hospitals, Strasbourg, France, 5Gilead Sciences, Inc., Foster City, CA, 6Gilead Sciences, Inc, San Diego, CA, 7Galapagos, NV, Mechelen, Belgium, 8Policlinico S. Matteo University, Pavia, Italy

    Background/Purpose: The preferential Janus kinase-1 inhibitor filgotinib (FIL) is approved to treat RA in Europe and Japan. We assessed FIL efficacy and safety in patients…
  • Abstract Number: 1699 • ACR Convergence 2021

    The “ITIS” Diet Improves Fatigue in Patients with Rheumatoid Arthritis and Is Associated with Changes in Metabolome and Fecal Microbiome

    Roxana Coras1, Cameron Martino1, Julia Gauglitz1, Alan Jarmusch1, Anupriya Tripathi1, Francesca Cedola2, Marta Fernandez-Bustamante1, Meritxall Agustín-Perez1, Maram Alharthi1, Susan Lee1, Abha Singh1, Soo In Choi1, Tania Rivera1, Katherine Nguyen3, Tatyana Shekhtman1, Tiffany Holt1, Shahrokh Golshan1, Rob Knight1, Pieter C Dorrestein1 and Monica Guma1, 1University of California San Diego, La Jolla, CA, 2University of California San Diego, Rome, CA, Italy, 3University of California San Diego, San Diego, CA

    Background/Purpose: Fatigue is common symptom in rheumatoid arthritis (RA), associated with decreased quality of life and productivity. Fatigue mechanisms have not been well studied, hence,…
  • Abstract Number: 1666 • ACR Convergence 2021

    Association of Objectively Measured Sleep Characteristics with Rheumatoid Arthritis Disease Activity

    Patricia Katz1, Sarah Patterson2, Mary Nakamura3, Aric Prather1, Laura Trupin4, Stephanie Rush1 and Katie Stone1, 1University of California San Francisco, San Francisco, CA, 2University of California San Francisco, Pacifica, CA, 3UCSF/SFVAHCS, San Francisco, CA, 4UC San Francisco, San Francisco, CA

    Background/Purpose: A large proportion of individuals with rheumatoid arthritis (RA), between 45%-70%, report sleep problems. Despite frequent reports of sleep problems, however, studies using objective…
  • « Previous Page
  • 1
  • …
  • 541
  • 542
  • 543
  • 544
  • 545
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology